Seeking Alpha
20 Jul 2026, 00:42 UTC · 18h ago
Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
20 Jul 2026, 00:42 UTC · 18h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
XmAb819 showed a 25% response rate and 70% disease control in heavily pre-treated ccRCC patients. — Strong clinical efficacy in a difficult-to-treat patient population suggests a high probability of therapeutic success.
+0.60Interim phase 2b data for XmAb942, a next-gen anti-TL1A for ulcerative colitis, is expected by the end of 2026. — Phase 2b data is a critical valuation catalyst for immunology pipelines, though the timeline is distant.
+0.40The pivotal study for XmAb819 is targeted for initiation in 2027. — While it confirms a path to market, the long timeframe reduces immediate price impact.
+0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company maintains a Strong Buy rating due to positive pipeline progress in oncology and inflammatory disorders.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1d ago
